

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**NICE guidelines**

**Equality and health inequalities assessment (EHIA)  
template**

**Intrapartum care – management of postpartum  
haemorrhage**

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

Update of table 12 in the NICE guideline on intrapartum care (NG235)

## Appendix B: equality and health inequalities assessment (EHIA)

### STAGE 1. Surveillance review

No surveillance review was carried out for this update.

### STAGE 2. Informing the scope

No scoping was carried out for this update.

### STAGE 3. Finalising the scope

No scoping was carried out for this update.

### STAGE 4. Development of guideline or topic area for update

*(to be completed by the developer before consultation on the draft guideline or update)*

Intrapartum care

Date of completion: 4 September 2024

Focus of guideline or update: Table 12 Choice of uterotonics for the treatment of postpartum haemorrhage because of uterine atony in the intrapartum care guideline (NG235)

4.1	From the evidence syntheses and the committee's considerations thereof, what were the main equality and health inequalities issues identified? Were any <b>further</b> potential issues identified (in addition to those identified during the scoping process) or any gaps in the evidence for any particular group?
	No scoping phase was carried out for this update.  Whilst we are aware of maternity being a key area in CORE20PLUS5, no equalities or health inequalities issues relevant to the specific update were identified by the committee.
4.2	How have the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the guideline or update and any draft recommendations?
	No equalities or health inequalities issues relevant to the update were identified by the committee.
4.3	Could any draft recommendations potentially increase inequalities?
	No.

4.4 How has the committee's considerations of equality and health inequalities issues identified in 2.2, 3.2 and 4.1 been reflected in the development of any research recommendations?
No equality and health inequalities issues relevant to the update were identified by the committee.
4.5 Based on the equality and health inequalities issues identified in 2.2, 3.2 and 4.1, do you have representation from relevant stakeholder groups for the guideline or update consultation process, including groups who are known to be affected by these issues? If not, what plans are in place to ensure relevant stakeholders are represented and included?
No equalities or health inequalities issues relevant to the update were identified by the committee. Various organisations that can provide comments in relation to equalities and health inequalities issues relevant to the update have been invited to register to become stakeholders.
4.6 What questions will you ask at the stakeholder consultation about the impact of the guideline or update on equality and health inequalities?
None.

Completed by developer \_\_\_\_\_ Maija Kallioinen \_\_\_\_\_

Date \_\_\_\_\_ 4 September 2024 \_\_\_\_\_

Approved by committee chair \_\_ Sarah Fishburn \_\_\_\_\_

Date \_\_ 15/9/24 \_\_\_\_\_

Approved by NICE quality assurance lead \_\_\_\_\_ Sara Buckner \_\_\_\_\_

Date \_\_\_\_\_ 18 September 2024 \_\_\_\_\_

